$129 Million is the total value of Foresite Capital Management III, LLC's 23 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 60.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALDR | Buy | Alder BioPharmaceuticals, Inc. | $31,312,000 | +312.4% | 1,278,570 | +456.2% | 24.23% | +259.8% |
| WVE | Buy | WAVE Life Sciences Ltd. | $17,855,000 | -20.6% | 1,411,749 | +0.1% | 13.82% | -30.8% |
| AERI | Buy | Aerie Pharmaceuticals, Inc. | $11,639,000 | +105.3% | 957,126 | +311.2% | 9.00% | +79.1% |
| GBT | Buy | Global Blood Therapeutics, Inc. | $7,882,000 | -47.0% | 497,000 | +8.0% | 6.10% | -53.8% |
| EPZM | Buy | Epizyme, Inc. | $5,779,000 | -21.9% | 476,777 | +3.3% | 4.47% | -31.8% |
| RGLS | Buy | Regulus Therapeutics Inc. | $5,468,000 | -12.8% | 789,091 | +9.7% | 4.23% | -23.9% |
| ARDX | New | Ardelyx, Inc. | $5,038,000 | – | 648,340 | +100.0% | 3.90% | – |
| AVXS | New | Avexis, Inc. | $4,582,000 | – | 168,195 | +100.0% | 3.54% | – |
| Buy | NeuroDerm Ltd. | $4,128,000 | -7.6% | 292,371 | +11.6% | 3.19% | -19.4% | |
| LPCN | Buy | Lipocine Inc. | $4,031,000 | -5.5% | 397,107 | +20.3% | 3.12% | -17.6% |
| SGMO | New | Sangamo Biosciences, Inc. | $3,296,000 | – | 544,816 | +100.0% | 2.55% | – |
| XLRN | Buy | Acceleron Pharma Inc. | $2,491,000 | +2.1% | 94,403 | +88.6% | 1.93% | -11.0% |
| BLCM | New | Bellicum Pharmaceuticals, Inc. | $1,926,000 | – | 205,990 | +100.0% | 1.49% | – |
| OREX | Buy | Orexigen Therapeutics, Inc. | $1,703,000 | -67.0% | 3,027,354 | +0.9% | 1.32% | -71.2% |
| BDSI | New | BioDelivery Sciences International, Inc. | $670,000 | – | 207,498 | +100.0% | 0.52% | – |
| EDIT | New | Editas Medicine, Inc. | $501,000 | – | 14,500 | +100.0% | 0.39% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-05-06
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Epizyme, Inc. | 24 | Q3 2021 | 17.6% |
| Acceleron Pharma Inc. | 22 | Q3 2021 | 25.9% |
| CymaBay Therapeutics, Inc. | 20 | Q3 2022 | 17.6% |
| Aerie Pharmaceuticals, Inc. | 18 | Q1 2020 | 33.5% |
| Ascendis Pharma A/S | 17 | Q3 2022 | 47.8% |
| Alder BioPharmaceuticals, Inc. | 16 | Q3 2019 | 27.4% |
| Natera, Inc. | 16 | Q3 2022 | 21.5% |
| Aimmune Therapeutics, Inc. | 16 | Q3 2019 | 8.1% |
| Verona Pharma PLC. | 15 | Q3 2022 | 30.0% |
| WAVE Life Sciences Ltd. | 15 | Q2 2019 | 20.0% |
View Foresite Capital Management III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 4 | 2021-11-03 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 3 | 2021-02-10 |
View Foresite Capital Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.